Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Rev

        
        1) Ogata, K et al. Clinical Safety, Tolerability, Pharmacokinetics, and
          Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J
          Clin Pharmacol. 2010;50:743-753.
        2) Clinicaltrials.gov: NCT00986154. Comparative Investigation of Low Molecular
          Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the
          Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots (The Edoxaban
          Hokusai-VTE Study). Available at: http://clinicaltrials.gov/show/NCT009861....
          [Last accessed: April 2013].
        3) Clinicaltrials.gov: NCT00781391. Global Study to Assess the Safety and
          Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in
          Patients With Atrial Fibrillation (ENGAGEAFTIMI48). Available at:
          http://clinicaltrials.gov/show/NCT007813.... [Last accessed: April 2013].
        4) Laulicht, B et al. Small Molecule Antidote for Anticoagulants. Circulation.
          2012:126;A11395.
        5) Perosphere Inc. Data on File.
        6) Bakhru, S et al. Small Molecule Antidote for Anticoagulants. Presentation at
          the Thrombosis and Hemostasis Summit of North America, Chicago, Illinois, May 4, 2012.
          Available at http://www.perosphere.com/pdf/PER977-THSNA-Presentation_Slid....
          [Last accessed: April 2013].
        7) Laulicht, B et al. Small Molecule Antidote for Anticoagulants. Presentation
          at the American Heart Association Meeting, Los Angeles, California, November 5, 2012.
          Available at: http://www.perosphere.com/pdf/PER977_AHA-presentation.pdf. [Last
          accessed: April 2013].
        8) Comp, P. Selective Factor Xa Inhibition Improves Efficacy of Venous
          Thromboembolism Prophylaxis in Orthopedic Surgery. Pharmacotherapy. 2003;23(6
          ):772-787.

CONTACT: Contact: Solomon S. Steiner, Ph.D., CEO, Perosphere Inc.,+1-914-241-0191, s.steiner@perosphere.com. Philip N. Sussman, CFO,Perosphere Inc., +1-212-769-0916, p.sussman@perosphere.com. MichaelaPaudler-Debus, PhD, Daiichi Sankyo Europe GmbH, +49-89-780-8685 (office).Daria Munsel, Daiichi Sankyo Europe, GmbH, +49-89-780-8728 (office).